IRVINE, Calif. - Biomerica Inc . (NASDAQ:BMRA) announced a multi-year exclusive distribution agreement with a leading healthcare conglomerate in the United Arab Emirates (UAE), aimed at improving cancer detection rates through the use of their at-home screening products. The agreement includes the distribution of Biomerica's EZ Detect™, a colorectal disease screening test, and Aware®, a device designed to aid in breast self-exams.
EZ Detect™ is an FDA-cleared, simple two-minute test that can be conducted at home without the need for stool handling. It detects occult blood in stool, which is an early indicator of colorectal cancer, the third most common cancer worldwide. The Dubai Healthcare Authority has recently approved insurance reimbursement for EZ Detect™, enhancing its affordability and accessibility within the UAE.
Aware® is another FDA-cleared product by Biomerica that increases sensitivity during breast self-exams, a crucial early detection method for breast cancer. Early detection is pivotal as approximately 80% of breast cancers are discovered by women noticing changes in their breasts, and survival rates can be as high as 99% when the cancer is found early.
The first order for both EZ Detect™ and Aware® has been placed, signifying the commencement of the partnership. The collaboration aims to integrate these tests into national health protocols and improve proactive health management in the Middle East.
Zack Irani, CEO of Biomerica, emphasized the significance of the partnership, stating that it supports a shift towards proactive health management and aligns with the company's commitment to early cancer detection. The strategic alliance is expected to enhance the distribution of Biomerica's health screening tools across the UAE and potentially introduce additional products to the region.
This move comes in response to the high incidence of colorectal cancer, which is the second leading cause of cancer death in the UAE. The test's design encourages regular screening and early detection, which is essential in the fight against cancer.
The information regarding this partnership and the products involved is based on a press release statement from Biomerica, Inc. The company continues to focus on developing diagnostic and therapeutic products that aim to enhance health while reducing healthcare costs.
InvestingPro Insights
Amidst the promising news of Biomerica Inc.'s (NASDAQ:BMRA) exclusive distribution agreement in the UAE, InvestingPro data presents a nuanced financial perspective on the company. The market capitalization of Biomerica stands at a modest $11.19 million, highlighting its position in the market as a smaller-cap company. The Price to Earnings (P/E) ratio, a measure of the company's current share price relative to its per-share earnings, is currently negative at -1.83, reflecting the company's lack of profitability in the last twelve months as of Q3 2024.
Furthermore, the company's revenue has seen a significant decline of 43.28% during the same period, indicating challenges in its financial performance. However, with a Price to Book (P/B) ratio of 1.44, the stock could be considered reasonably valued in terms of its assets and liabilities.
InvestingPro Tips suggest that while Biomerica holds more cash than debt on its balance sheet and liquid assets exceed short term obligations, it is quickly burning through cash. This could be a concern for investors looking at the company's financial sustainability. Additionally, analysts predict the company will be profitable this year, which could signal a turnaround from its current financial status.
For those seeking more in-depth analysis, InvestingPro offers additional tips on Biomerica, including insights on sales growth expectations and stock price movements. Interested readers can explore these valuable tips by visiting the InvestingPro platform for Biomerica at https://www.investing.com/pro/BMRA. To enhance your InvestingPro experience, use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription. There are 13 additional InvestingPro Tips available for Biomerica, providing a comprehensive view for informed investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.